FATE News and Press, Fate Therapeutics Inc. From 05/04/22

Fate Therapeutics press release (NASDAQ:FATE): Q1 GAAP EPS of -$0.68 beats by $0.11. Revenue of $18.4M (+65.2% Y/Y) beats by $9.39M. For further details see: Fate Therapeutics GAAP EPS of -$0.68 beats by $0.11, revenue of $18.4M beats by $9.39M

FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL FT596+R-CHOP Clinical Protocol for First-line Investigation to be Submitted to FDA in 2Q22 FT819 Enrollment Ongoing in Single- and Multi-dose Cohorts for R/R BCL in Landmark Study of Of...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with canc...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the un...

Shares of Fate Therapeutics Inc. (NASDAQ:FATE) traded today at $121.00, eclipsing its 52-week high. This new high was reached on above average trading volume as 62 million shares traded hands, while the average 30-day volume is approximately 1.3 million shares. There is potential upside ...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q4-2021 13F filings the consensus holdings were updated, 7 stocks were removed and 7 added from the unive...

Gainers: Qurate Retail (QRTEA) +19%. lululemon athletica  (LULU) +7%. Cue Health  (HLTH) +7%. Spero Therapeutics (SPRO) +6%. Applied Molecular Transport  (AMTI) +6%. Losers: Stronghold Digital Mining (SDIG) -26%. Braze (BRZE) -11%. Global-E Online ...

The SPDR S&P Biotech ETF is down close to 25% year-to-date but Michael Yee sees several names in this space that look promising at current valuations. Why did XBI recover in recent weeks? Interestingly, XBI is down by that much despite a 10% rebound over the past two wee...